Cantor Fitzgerald Lowers Earnings Estimates for Humacyte

Humacyte, Inc. (NASDAQ:HUMA) – Equities researchers at Cantor Fitzgerald reduced their FY2024 earnings per share (EPS) estimates for Humacyte in a note issued to investors on Monday, November 11th. Cantor Fitzgerald analyst K. Kluska now anticipates that the company will earn ($1.41) per share for the year, down from their previous estimate of ($1.23). Cantor Fitzgerald has a “Overweight” rating and a $13.00 price objective on the stock. The consensus estimate for Humacyte’s current full-year earnings is ($1.22) per share.

Humacyte (NASDAQ:HUMA) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.04).

Several other equities analysts have also recently weighed in on HUMA. BTIG Research reaffirmed a “buy” rating and issued a $10.00 price target on shares of Humacyte in a research report on Friday, October 18th. HC Wainwright restated a “buy” rating and issued a $12.00 target price on shares of Humacyte in a report on Wednesday. Benchmark reiterated a “buy” rating and set a $15.00 price target on shares of Humacyte in a report on Thursday, October 10th. EF Hutton Acquisition Co. I raised Humacyte to a “strong-buy” rating in a research report on Monday, September 9th. Finally, Piper Sandler set a $6.00 price objective on shares of Humacyte and gave the stock a “neutral” rating in a report on Friday, October 18th. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $11.00.

Humacyte Price Performance

Humacyte stock opened at $4.84 on Thursday. The firm has a market capitalization of $577.06 million, a price-to-earnings ratio of -3.61 and a beta of 1.47. The firm’s fifty day moving average price is $5.43 and its two-hundred day moving average price is $6.16. Humacyte has a 1-year low of $2.35 and a 1-year high of $9.97. The company has a current ratio of 1.10, a quick ratio of 5.41 and a debt-to-equity ratio of 0.61.

Institutional Trading of Humacyte

Several hedge funds have recently made changes to their positions in HUMA. Endowment Wealth Management Inc. raised its stake in Humacyte by 3.1% in the 2nd quarter. Endowment Wealth Management Inc. now owns 100,518 shares of the company’s stock valued at $482,000 after acquiring an additional 3,000 shares during the period. nVerses Capital LLC bought a new stake in shares of Humacyte in the second quarter valued at approximately $28,000. Private Advisor Group LLC lifted its stake in shares of Humacyte by 1.8% during the 3rd quarter. Private Advisor Group LLC now owns 373,110 shares of the company’s stock valued at $2,030,000 after buying an additional 6,510 shares in the last quarter. The Manufacturers Life Insurance Company boosted its holdings in Humacyte by 32.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 34,919 shares of the company’s stock worth $168,000 after buying an additional 8,557 shares during the period. Finally, China Universal Asset Management Co. Ltd. grew its stake in Humacyte by 64.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 22,955 shares of the company’s stock valued at $125,000 after buying an additional 8,965 shares in the last quarter. 44.71% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, CEO Laura E. Niklason sold 277,090 shares of Humacyte stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $6.47, for a total value of $1,792,772.30. Following the sale, the chief executive officer now owns 4,029,374 shares of the company’s stock, valued at approximately $26,070,049.78. The trade was a 6.43 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Brady W. Dougan sold 352,112 shares of the stock in a transaction on Thursday, August 29th. The shares were sold at an average price of $6.35, for a total value of $2,235,911.20. Following the transaction, the director now directly owns 3,677,262 shares of the company’s stock, valued at approximately $23,350,613.70. This trade represents a 8.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,084,153 shares of company stock valued at $6,869,996. Insiders own 11.20% of the company’s stock.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.